Practical Implications for Treatment Strategies in Advanced Ovarian Cancer

EP. 1: An Introduction to the Discussion of Ovarian Cancer

July 20th 2020

EP. 2: Biomarker-Driven Frontline Ovarian Cancer Treatment

July 20th 2020

EP. 3: The Impact of PAOLA-1 on Frontline Treatment of Ovarian Cancer

July 20th 2020

EP. 4: Impact of HRD Status on Frontline Treatment of Ovarian Cancer

July 20th 2020

EP. 5: Need for Frontline Comparison Trials in Ovarian Cancer

July 20th 2020

EP. 6: Treating BRCA+ Ovarian Cancer

July 20th 2020

EP. 7: Treating Homologous Recombination Proficient Ovarian Cancer

July 20th 2020

EP. 8: Personalized Dosing of Niraparib in Ovarian Cancer

July 20th 2020

EP. 9: NCCN Guidelines and FDA Approvals for Treating Ovarian Cancer

July 20th 2020

EP. 10: PAOLA-1 Study Surgical Subset for Ovarian Cancer

July 20th 2020

EP. 11: Patient Preference for Treatment in Ovarian Cancer

July 20th 2020

EP. 12: Emerging Combinations in the Frontline Setting of Ovarian Cancer

July 20th 2020

EP. 13: Expert Approaches for Treating Recurrent Ovarian Cancer

July 20th 2020

EP. 14: PARP Inhibitors in Recurrent Ovarian Cancer

July 20th 2020

EP. 15: New Data for Secondary Surgery in Ovarian Cancer

July 20th 2020

EP. 16: Neoadjuvant Therapy Versus Surgery for Ovarian Cancer

July 20th 2020

EP. 17: Antibody Drug Conjugates for Ovarian Cancer

July 20th 2020

EP. 18: Emerging Therapies in Recurrent Ovarian Cancer

July 20th 2020

EP. 19: Upcoming Clinical Trials for Ovarian Cancer

July 20th 2020